Comparative in vitro activity of piperacillin-tazobactam and temocillin against third-generation cephalosporin-resistant, carbapenem-susceptible Escherichia coli and Klebsiella pneumoniae.
CTX-M
ESBL
Enterobacteriaceae
Germany
Journal
GMS infectious diseases
ISSN: 2195-8831
Titre abrégé: GMS Infect Dis
Pays: Germany
ID NLM: 101694381
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
2
2
2022
pubmed:
3
2
2022
medline:
3
2
2022
Statut:
epublish
Résumé
Carbapenems are considered the drugs of choice for first-line treatment of severe infections caused by carbapenem-susceptible, extended-spectrum β-lactamases (ESBL)-producing Enterobacterales, while piperacillin-tazobactam has been recommended as an alternative for treatment of non-severe infections. Temocillin is stable to ESBL and AmpC enzymes and may thus represent another treatment option. This study assessed the in vitro activity of piperacillin-tazobactam and temocillin against third-generation cephalosporin (3GC)-resistant
Identifiants
pubmed: 35106270
doi: 10.3205/id000077
pii: id000077
pmc: PMC8777484
doi:
Banques de données
Dryad
['10.5061/dryad.931zcrjkc']
Types de publication
Journal Article
Langues
eng
Pagination
Doc08Informations de copyright
Copyright © 2021 Kresken et al.
Déclaration de conflit d'intérêts
MK is a partner and CEO of Antiinfectives Intelligence GmbH, a research organization providing services to pharmaceutical companies. YP and GW declare that they have no competing interests.
Références
Int J Antimicrob Agents. 2021 Jan;57(1):106223
pubmed: 33166691
Int J Antimicrob Agents. 2018 Jul;52(1):100-103
pubmed: 29580930
Clin Microbiol Rev. 2009 Jan;22(1):161-82, Table of Contents
pubmed: 19136439
Clin Microbiol Rev. 2005 Oct;18(4):657-86
pubmed: 16223952
Clin Microbiol Infect. 2019 Aug;25(8):932-942
pubmed: 30986558
J Antimicrob Chemother. 2015 Mar;70(3):891-8
pubmed: 25433006
Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1185-1191
pubmed: 32096107
GMS Infect Dis. 2021 Dec 21;9:Doc08
pubmed: 35106270
Clin Microbiol Rev. 2018 Feb 14;31(2):
pubmed: 29444952
Lancet Infect Dis. 2013 Sep;13(9):785-96
pubmed: 23969216
Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):E3463-E3470
pubmed: 29581252
J Antimicrob Chemother. 2011 Jan;66(1):37-47
pubmed: 21036771